Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 26, 621–623 (1 June 2008) | doi:10.1038/nbt0608-621
The FDA and safety|[mdash]|beyond the heparin crisis
&
Abstract
Interest in drug safety has grown as a result of several high-profile market withdrawals of approved drugs, particularly over the past few years. In the latest incident, the anticoagulant heparin sodium—an essential drug for use in surgery, hemodialysis and the treatment of chronic conditions, such as heart failure and deep vein thrombosis—has been found to contain traces of a contaminant associated with hundreds of adverse events.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
